<DOC>
	<DOCNO>NCT01267578</DOCNO>
	<brief_summary>The purpose study evaluate overall survival immunological monitoring peptide vaccination therapy use novel cancer testis antigen ( STF-II ) locally advanced , recurrent , metastatic esophageal squamous cell carcinoma</brief_summary>
	<brief_title>Peptide Vaccination Treating Patients With Esophageal Cancer ( STF-II )</brief_title>
	<detailed_description>The phase II multicenter trial vaccination study use peptide derive URLC10 , CDCA1 , KOC1 locally advance , recurrent metastatic esophageal squamous cell carcinoma ( ESCC ) fail standard therapy perform evaluate survival benefit cancer vaccination .</detailed_description>
	<mesh_term>Esophageal Neoplasms</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>DISEASE CHARACTERISTICS 1 . Locally advanced , recurrent metastatic esophageal squamous cell carcinoma fail standard therapy PATIENTS CHARACTERISTICS 1 . ECOG performance status 02 2 . Age≧20 year , 80≦years 3 . WBC≥ 2,000/mm³ Platelet count ≥ 75,000/mm³ Total bilirubin ≤ 2.0 x institutional normal upper limit AST , ALT , ALP ≤ 2.5 x institutional normal upper limit Creatinine ≤ 1.5 x institutional normal upper limit 4 . No therapy 4 week prior initiation trial 5 . Able willing give valid write informed consent 1 . Pregnancy ( woman childbearing potential : Refusal inability use effective mean contraception ) 2 . Breastfeeding 3 . Serious bleed disorder 4 . Serious infection require antibiotic 5 . Concomitant treatment steroid immunosuppressing agent 6 . Decision unsuitableness principal investigator physicianincharge</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>December 2010</verification_date>
	<keyword>Epitope peptide , CTL , Esophageal cancer , Vaccination</keyword>
</DOC>